Catalyst Pharmaceuticals Inc. Daily Stock Analysis

Daily Stock Analysis, CPRX, Catalyst Pharmaceuticals Inc, priceseries

Catalyst Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
7.63
Close
7.71
High
7.87
Low
7.62
Previous Close
7.63
Daily Price Gain
0.08
YTD High
8.30
YTD High Date
Mar 2, 2022
YTD Low
5.24
YTD Low Date
Jan 28, 2022
YTD Price Change
0.79
YTD Gain
11.42%
52 Week High
8.30
52 Week High Date
Mar 2, 2022
52 Week Low
3.49
52 Week Low Date
Mar 8, 2021
52 Week Price Change
4.19
52 Week Gain
119.03%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 13. 2017
1.14
Apr 4. 2017
1.78
16 Trading Days
55.71%
Link
LONG
Jun 19. 2017
2.39
Jul 13. 2017
2.74
17 Trading Days
14.84%
Link
LONG
Apr 23. 2018
2.56
May 3. 2018
2.75
8 Trading Days
7.56%
Link
LONG
May 11. 2018
2.94
May 25. 2018
3.29
10 Trading Days
11.87%
Link
LONG
Jan 2. 2019
2.11
Jan 22. 2019
2.52
13 Trading Days
19.60%
Link
LONG
Feb 8. 2019
2.47
Feb 28. 2019
2.74
13 Trading Days
10.86%
Link
LONG
Mar 18. 2019
3.08
Apr 17. 2019
5.23
22 Trading Days
69.87%
Link
LONG
Aug 13. 2019
5.30
Aug 23. 2019
5.68
8 Trading Days
7.22%
Link
LONG
Feb 4. 2020
4.25
Feb 24. 2020
4.93
13 Trading Days
15.92%
Link
LONG
Feb 1. 2021
3.88
Feb 12. 2021
4.20
9 Trading Days
8.18%
Link
LONG
Mar 12. 2021
3.89
Mar 24. 2021
4.29
8 Trading Days
10.30%
Link
LONG
May 12. 2021
4.86
May 25. 2021
5.44
9 Trading Days
11.98%
Link
LONG
Oct 4. 2021
5.33
Oct 18. 2021
6.01
10 Trading Days
12.68%
Link
LONG
Nov 10. 2021
6.45
Nov 26. 2021
7.19
11 Trading Days
11.44%
Link
LONG
Feb 7. 2022
6.54
Feb 24. 2022
7.24
12 Trading Days
10.70%
Link
Company Information
Stock Symbol
CPRX
Exchange
NasdaqCM
Company URL
http://www.catalystpharma.com
Company Phone
(305) 529-2522
CEO
Patrick J. McEnany
Headquarters
Florida
Business Address
355 ALHAMBRA CIRCLE, SUITE 1250, CORAL GABLES, FL 33134
Sector
Equity
Industry Category
Drugs
Industry Group
Drugs - Generic
CIK
0001369568
About

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on development and commercialization of prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette's disorder. The company was founded by McEnany J. Patrick and Huckel E. Hubert in January 2002 and is headquartered in Coral Gables, FL.

Description

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for people with rare debilitating diseases. Its lead product candidate is Firdapse, a proprietary form of amifampridine phosphate, which is in second Phase III clinical trials for the treatment of patients with Lambert-Eaton Myasthenic syndrome; and is in small blinded clinical trial to treat Congenital Myasthenic syndromes, as well as is in Phase II/III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis. The company also develops CPP-115, a gamma-aminobutyric acid aminotransferase inhibitor that is in Phase Ib clinical trial for the treatment of epilepsy, infantile spams, and Tourette's disorder; and CPP-109 to treat Tourette's disorder. It has a strategic collaboration with BioMarin Pharmaceutical Inc. for the development of Firdapse. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading